Avita Medical (RCEL) to Release Quarterly Earnings on Thursday

Avita Medical (NASDAQ:RCEL) is projected to announce its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect the company to announce earnings of ($0.36) per share and revenue of $26.27 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 12, 2026 at 4:30 PM ET.

Avita Medical (NASDAQ:RCEL) last posted its earnings results on Thursday, November 6th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03). The business had revenue of $17.06 million during the quarter, compared to analysts’ expectations of $29.39 million. On average, analysts expect Avita Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Avita Medical Stock Down 5.1%

RCEL opened at $4.08 on Thursday. Avita Medical has a 52 week low of $3.22 and a 52 week high of $11.25. The stock has a market cap of $124.40 million, a PE ratio of -2.25 and a beta of 1.78. The business has a 50 day moving average of $3.68 and a 200-day moving average of $4.38.

Analyst Ratings Changes

Several equities analysts have commented on RCEL shares. D. Boral Capital reissued a “buy” rating and set a $10.00 price objective on shares of Avita Medical in a research report on Monday, January 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Avita Medical in a research note on Monday, December 29th. Zacks Research raised shares of Avita Medical from a “strong sell” rating to a “hold” rating in a research report on Friday, December 19th. BTIG Research raised shares of Avita Medical from a “sell” rating to a “neutral” rating in a research note on Thursday, November 20th. Finally, Lake Street Capital upped their price objective on shares of Avita Medical from $3.00 to $3.50 and gave the stock a “hold” rating in a report on Friday, January 16th. One research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $5.50.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company purchased a new stake in shares of Avita Medical during the second quarter valued at approximately $58,000. Strs Ohio purchased a new position in Avita Medical in the 1st quarter worth approximately $116,000. Curi Capital LLC bought a new position in Avita Medical in the 2nd quarter valued at approximately $100,000. XTX Topco Ltd purchased a new stake in Avita Medical during the 2nd quarter valued at $153,000. Finally, Gabelli Funds LLC bought a new stake in shares of Avita Medical in the 2nd quarter worth $185,000. 27.66% of the stock is owned by hedge funds and other institutional investors.

Avita Medical Company Profile

Avita Medical, Inc (NASDAQ: RCEL) is a regenerative medicine company focused on the development and commercialization of cell‐based therapies for acute and chronic wounds. Its flagship technology, the ReCell® Autologous Cell Harvesting Device, enables clinicians to create a suspension of a patient’s own skin cells at the point of care. The system is designed to accelerate wound healing, minimize donor‐site requirements and reduce scarring for patients suffering from burns, traumatic wounds and a variety of surgical and reconstructive procedures.

Founded in 2009 and headquartered in Carlsbad, California, Avita Medical has secured regulatory clearances in key markets, including CE mark approval in the European Union and 510(k) clearance from the U.S.